Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988- 1994). The Seroco Study Group

Abstract

Method. The influence of age at infection on progression of human immunodeficiency virus (HIV) disease to different clinical endpoints was studied among 393 HIV-seropositive adults selected from the French SEROCO cohort; follow-up lasted from January 1988 to November 1994. Selected patients had a known date of infection and were enrolled shortly after seroconversion. Age-associated risk ratios (RR) were estimated using the Cox model (age fitted as a continuous variable and RR expressed for each 10-year increment after adjustment for symptomatic primary infection and sexual preference). Results. Age had a weak influence on progression from the date of infection to the first category B event (crude RR = 1.15; adjusted RR = 1.09; 95% confidence interval [CI] : 0.89-1.36) but a marked influence on progression from the first category B to the first category C event (crude RR = 1.95; adjusted RR = 1.97; 95% CI : 1.37-2.79). Similar results were obtained after adjustment for the CD4 + cell count at enrolment. A qualitative CD4 + cell defect could explain the influence of age, but this remains to be confirmed. Conclusion. Age at infection should be included in the definition of CD4 + cell count thresholds for clinical management and treatment initiation. Risk factors for progression should be assessed according to the different clinical endpoints.

Cost-Effectiveness of an Intervention to Reduce HIV/STI Incidence and Promote Condom Use among Female Sex Workers in the Mexico–US Border Region

“…Overall HIV incidence rates were close to the CDC estimates for Latino women in the U.S. at 11.2 per 100,000 [28]. Similar to findings from other cohorts [29], median survival post-HIV infection predicted by the model was 12 years (interquartile range [IQR]: 9–14) when HAART was not considered in the model, and varied according to the age when HIV infection was acquired, showing increased survival for women infected at younger ages. Considering HAART initiation based on clinical CD4 count thresholds [19], the median survival post-HIV infection was 24 years (IQR: 12–35).…”

Age, sex, and nutritional status modify the CD4+ T-cell recovery rate in HIV–tuberculosis co-infected patients on combination antiretroviral therapy

“…Some epidemiologic studies have associated older age at HIV infection with faster progression to AIDS in the pre-ART era[8, 9]. However, results of investigations of age-associated differences in CD4+T-cell response for HIV-infected adults on HAART have been more variable in the context of cART[10, 11].…”

Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital

“…These factors include but are not restricted to level of adherence, baseline CD4 lymphocyte count, baseline viral load, hemoglobin, total lymphocyte count, WHO HIV disease stage, and Alanine transaminase (ALT) among others. 30–32 …”